Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lisaftoclax plus IA/MDAC chemotherapy in treatment-naïve AML (CD69 biomarker study)
ChiCTR2600117988Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lisaftoclax in acute myeloid leukemia (AML) (2 arms), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoint: Composite complete remission rate (CRc). Planned start Jan 2026; status: not yet recruiting.
02
Drugs
lisaftoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2600117988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117988.